Portola Pharmaceuticals, Inc.

Wm Wrigley Jr Company

Cor Therapeutics, Inc.

Millennium Pharmaceuticals Limited

Other

Alexion Pharmaceuticals, Inc.

Millenium Pharmaceuticals, Inc.

The Cbr Institute for Biomedical Research, Inc.

Cbr, Inc.

David R Phillips

Patrick Andre

Uma Sinha

Genmin Lu

Shengfeng Li

Denisa D Wagner

Robert M Scarborough

Anjali Pandey

Xiaoming Zhang

Mansukh M Patel

Michael A Reed

David G Barkalow

Xiaohu Xia

Jean-Pierre Cazenave

Deborah Ann Law

Francois Lanza

Charles Homcy

Gillian Stephens

Wolin Huang

Noah Ziman Pentelovitch

Israel F Charo

Vanitha Ramakrishnan

Mukund Mehrotra

Neema Pourian

Pamela B Conley

Jingping Liu

Marcia Petit

Philip W Urnezis

Chungsea Shen

Xiaoqun Mo

Leslie D Morgret

Veronica Alves

Shashi Mishra

Sri R Prasad

Atanu Palit

Vinod Vibhute

Vijender Singh

Lisa Nannizzi Alaimo

Laurence A Fitzgerald

Les Morgret

Rafael Bras

Hilary Cannon

Philip Shepherd

Lisa Alaimo

April J Tackett

Les D Morgret

Thomas Richard Koziel

Rafael E Bras

Craig M Grant

Caren Chin

Ann Allanson

April Hsu

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Antidotes for factor Xa inhibitors and methods of using the same

A chewing gum base comprises rubber derived from Russian Dandelion (TKS). Methods of extracting and purifying the rubber are provided. Gum base compositions and methods of compensating for variable ratios of elastomer:resin in the rubber are disclosed.

Gum bases incorporating polymers derived from Russian Dandelion

Methods for identifying carbon derived from natural sources in a confectionary product are presented. Methods include separating, extracting and carbon dating components of a confectionary product, e.g., chewing gum or chewing gum base.

Methods for identifying carbon derived from natural sources

Dried fruit powders are used as a replacement for current bulking agents used in chewing gum, such as polyols or sucrose, thereby providing healthier chewing gum options to consumers with real fruit taste.

Chewing gum compositions based on dried fruit powders

A multi-piece dispenser for confectionary products including a housing defining an inner chamber for storing a multi-piece package of confectionary product including a slot for receiving an end portion of the multi-piece package for dispensing the confectionary product and a retention member for retaining the end portion of the package within the slot for further dispensing.

Multi-piece dispenser for use with a consumable product

Chewing gums and chewing gum bases which are cud-forming and chewable at mouth temperature contains a block copolymer having at least two hard crystallizable polymeric blocks and at least one soft polymeric block. At least one hard polymeric block is a hard crystallizable polymeric block has a melting point greater than 20&#xb0; C. The hard, crystallizable polymeric blocks and the soft blocks each have a degree of polymerization of at least 15 Characteristics of the block copolymers can be selected to produce gum bases and chewing gums having desired properties. In some cases, chewed cuds formed from the gum bases may exhibit improved removability from environmental surfaces to which they may become undesirably attached.

Chewing gums and gum bases comprising block copolymers having crystallizable hard blocks

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Antidotes for factor XA inhibitors and methods of using the same

The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.

Methods of treatment with Syk inhibitors

The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

Device and methods for identifying and treating aspirin non-responsive patients

Growing community of inventors

San Mateo, CA, United States of America

David R Phillips